Literature DB >> 8289392

An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.

H D White1, D A Roeder, W R Green.   

Abstract

H-2b tumor cells expressing the endogenous ecotropic murine leukemia virus (EMV) induce an anti-AKR/Gross murine leukemia virus (MuLV) cytotoxic T-lymphocyte (CTL) response in the C57BL/6 mouse strain. The EMV clone AKR623 has been used to infect SC.Kb fibroblast cells, resulting in SC.Kb/623 targets that are lysed by bulk anti-AKR/Gross MuLV CTL with a profile that is similar to that for the EMV+ AKR.H-2b SL1 tumor target. Anti-AKR/Gross MuLV CTL are restricted by the class I Kb antigen and do not cross-react with Friend-Moloney-Rauscher virus-positive targets. The AKR623 genome was searched by computer for coding sequences that fit the motif XXXX(FY)XX(VIML) for peptides that bind Kb. Of 30 octameric peptides identified, 12 that were unique to AKR623 and different from published Friend-Moloney-Rauscher sequences were synthesized and bound to EMV-negative SC.Kb cells, which were then assayed as targets against anti-AKR/Gross MuLV CTL. One peptide, peptide 12 (KSPWFTTL) from the p15E transmembrane protein, sensitized SC.Kb target cells to lysis by anti-AKR/Gross MuLV CTL with a profile similar to those seen for AKR.H-2b SL1 tumor targets and SC.Kb/623 fibroblast targets. Low concentrations of peptide were sufficient, the half-maximal lysis occurring at 10 to 100 pg/ml. SC.Kb/peptide 12 targets were recognized by the H-2b-restricted bulk CTL in a conventional class I Kb-restricted fashion. Unlabeled SC.Kb/peptide 12-pulsed targets were effective in competing with radiolabeled SC.Kb/623 targets for lysis by anti-AKR/Gross MuLV CTL. This finding is consistent with the notion that peptide 12 represents the dominant endogenously processed epitope recognized by these antiviral CTL. In addition, peptide 12 is immunogenic in that it could stimulate the in vitro generation of an anti-AKR/Gross MuLV CTL response from tumor-primed C57BL/6 responder spleen cells. Finally, the physiological relevance of peptide 12 was suggested by its ability to fully restore the recognition and lysis of AKR.H-2b SL1 clone 18-5 tumor cells, a naturally occurring variant tumor clone that is insusceptible to lysis by anti-AKR/Gross MuLV CTL. These data indicate that a virus-encoded antigen, represented by peptide 12, and not a nonviral tumor antigen, is the immunodominant epitope responsible for the recognition of EMV+ tumor cells by C57BL/6-derived anti-AKR/Gross MuLV CTL.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289392      PMCID: PMC236526          DOI: 10.1128/JVI.68.2.897-904.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb.

Authors:  D H Fremont; M Matsumura; E A Stura; P A Peterson; I A Wilson
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

Review 2.  Molecular components of T-cell recognition.

Authors:  J L Jorgensen; P A Reay; E W Ehrich; M M Davis
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

3.  Resistance to cellular immune response in AKR leukemias.

Authors:  A Schäfer; W Schmidt
Journal:  Eur J Immunol       Date:  1986-07       Impact factor: 5.532

4.  Specificity of cytolytic T cells directed against AKR/Gross virus-induced syngeneic leukemias: antibodies directed against H-2K, but not against viral proteins, inhibit lysis.

Authors:  W R Green; R C Nowinski; C S Henney
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

5.  The generation and specificity of cytotoxic T cells raised against syngeneic tumor cells bearing AKR/Gross murine leukemia virus antigens.

Authors:  W R Green; R C Nowinski; C S Henney
Journal:  J Exp Med       Date:  1979-07-01       Impact factor: 14.307

6.  The structure of the antigen-binding groove of major histocompatibility complex class I molecules determines specific selection of self-peptides.

Authors:  G M van Bleek; S G Nathenson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

7.  Immune response to Moloney murine leukemia virus nonviral, tumor-associated antigens fails to provide in vivo tumor protection.

Authors:  D Jiang; D C Flyer
Journal:  J Immunol       Date:  1992-02-01       Impact factor: 5.422

8.  H-2-restricted cytolytic T lymphocytes specific for a subclass of AKR endogenous leukemia virus-induced tumors: correlation of tumor cell susceptibility with expression of the gross cell surface antigen.

Authors:  W R Green
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

9.  Vesicular stomatitis virus antigenic octapeptide N52-59 is anchored into the groove of the H-2Kb molecule by the side chains of three amino acids and the main-chain atoms of the amino terminus.

Authors:  K Shibata; M Imarai; G M van Bleek; S Joyce; S G Nathenson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

10.  Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes.

Authors:  E G Pamer; J T Harty; M J Bevan
Journal:  Nature       Date:  1991-10-31       Impact factor: 49.962

View more
  15 in total

1.  Spontaneous priming for anti-viral envelope cytotoxic T lymphocytes in mice transgenic for a murine leukaemia virus envelope gene (Fv4).

Authors:  A Nihrane; J Silver
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

2.  Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors.

Authors:  W Chen; H Qin; B Chesebro; M A Cheever
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 3.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

4.  Immunization against endogenous retroviral tumor-associated antigens.

Authors:  M H Kershaw; C Hsu; W Mondesire; L L Parker; G Wang; W W Overwijk; R Lapointe; J C Yang; R F Wang; N P Restifo; P Hwu
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

5.  Antiretroviral cytolytic T-lymphocyte nonresponsiveness: FasL/Fas-mediated inhibition of CD4(+) and CD8(+) antiviral T cells by viral antigen-positive veto cells.

Authors:  R F Rich; W R Green
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Naturally occurring TAP-dependent specific T-cell tolerance for a variant of an immunodominant retroviral cytotoxic T-lymphocyte epitope.

Authors:  V Kim; J W Yewdell; W R Green
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Adoptive transfer of polyclonal and cloned cytolytic T lymphocytes (CTL) specific for mouse AIDS-associated tumors is effective in preserving CTL responses: a measure of protection against LP-BM5 retrovirus-induced immunodeficiency.

Authors:  W R Green; K A Green; K M Crassi
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  AKR.H-2b lymphocytes inhibit the secondary in vitro cytotoxic T-lymphocyte response of primed responder cells to AKR/Gross murine leukemia virus-induced tumor cell stimulation.

Authors:  R F Rich; W R Green
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Age-dependent tolerance to an endogenous tumor-associated antigen.

Authors:  Jennifer A McWilliams; Richard T Sullivan; Kimberly R Jordan; Rachel H McMahan; Charles B Kemmler; Marcia McDuffie; Jill E Slansky
Journal:  Vaccine       Date:  2008-02-20       Impact factor: 3.641

Review 10.  The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses.

Authors:  Tania Løve Aaes; Peter Vandenabeele
Journal:  Cell Death Differ       Date:  2020-11-19       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.